The shares of Senores Pharmaceuticals Limited were trading at ₹570.70 up by ₹36.90 or 6.91 per cent on the NSE today at 2.32 pm.
Senores Pharmaceuticals Limited announced the acquisition of US marketing rights for Roflumilast tablets through its American subsidiary. The deal with Breckenridge Pharmaceutical, Inc., a subsidiary of Towa International, includes the USFDA-approved Abbreviated New Drug Application (ANDA) for 250 mcg and 500 mcg tablets.
Roflumilast is used to reduce COPD exacerbations in patients with severe chronic bronchitis. The US market for the drug was valued at approximately $32 million as of June 2024, according to IQVIA data, and $46 million as of September 2024, per Symphony.
- Also read: MRO-TEK Realty rebrands as Umiya Buildcon Limited
The Ahmedabad-based company plans to manufacture the drug at its US facility and will fund the acquisition using proceeds from its recent IPO. Managing Director Swapnil Shah said the acquisition aligns with the company’s strategy to enter niche, under-penetrated generic formulations.
Senores currently has 24 ANDAs and 21 CMO/CDMO commercial products approved for US distribution. The company operates two formulation manufacturing facilities – an FDA-approved plant in Atlanta, USA, and a WHO-GMP approved facility in Chhatral, India. It also maintains two API manufacturing facilities near Ahmedabad and three R&D sites across India and the USA.
